We conclude that, in addition to its role on lymphatic and endothelial vasculature, the specific VEGFR-3 inhibitor SAR131675 has an anti tumor effect by acting on different mechanisms through which key players of the inflammatory response orchestrate tumor progress, confirming that VEGFR-3 axis is an interesting therapeutic target for cancer treatment. The gene discussed is FLT4; the disease is cancer.